| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
iMDK manufacturers
- iMDK
-
- $54.00
-
2026-07-27
- CAS:881970-80-5
- Purity: 99.99%
- Supply Ability: 10g
|
| Product Name: | iMDK | | Synonyms: | iMDK;3-[2-(4-Fluoro-benzyl)-imidazo[2,1-b]thiazol-6-yl]-chromen-2-one;2H-1-Benzopyran-2-one, 3-[2-[(4-fluorophenyl)methyl]imidazo[2,1-b]thiazol-6-yl]-;inhibit,iMDK,midkine,factor,PI3K,NSCLC,growth,Inhibitor,Phosphoinositide 3-kinase,MDK;3-[2-[(4-Fluorophenyl)methyl]imidazo[2,1-b]thiazol-6-yl]-2H-1-benzopyran-2-one;3-(2-(4-Fluorobenzyl)imidazo[2,1-b]thiazol-6-yl)-2H-chromen-2-one;iMDK, 10 mM in DMSO | | CAS: | 881970-80-5 | | MF: | C21H13FN2O2S | | MW: | 376.4 | | EINECS: | | | Product Categories: | | | Mol File: | 881970-80-5.mol |  |
| density | 1.42±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C, protect from light | | solubility | Limited solubility | | pka | 5.71±0.40(Predicted) | | form | Solid | | color | Off-white to yellow | | InChI | InChI=1S/C21H13FN2O2S/c22-15-7-5-13(6-8-15)9-16-11-24-12-18(23-21(24)27-16)17-10-14-3-1-2-4-19(14)26-20(17)25/h1-8,10-12H,9H2 | | InChIKey | IWFKQTWYILKFGE-UHFFFAOYSA-N | | SMILES | C1(=O)OC2=CC=CC=C2C=C1C1=CN2C=C(CC3=CC=C(F)C=C3)SC2=N1 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| Uses | iMDK is a small molecule inhibitor used to bind to midkine (MDK), a heparin binding growth factor that is expressed in malignant tumors. | | Biological Activity | Cell permeable: yes', 'Primary Target
Midkine', 'Reversible: yes | | in vivo | The combination treatment of iMDK ( (9 mg/kg/day; intraperitoneally injected with 100 μl) and PD0325901 (5 mg/kg; orally administered) effectively reduced lung tumor growth in a xenograft mouse model[1]. | Animal Model: | female BALB/c nude mice (6 week old) bearing H441 human lung cancer xenografts[1] | | Dosage: | iMDK (9 mg/kg) and PD0325901 (5 mg/kg) | | Administration: | Intraperitoneally injected with 100 μL iMDK everyday and/or orally administered PD0325901 five times per week (on days 1, 2, 3, 4, 5, 7, 8, 9, 10, 11) | | Result: | Reduced significantly volume of the tumors derived from H441 lung adenocarcinoma cells after the combination treatment with iMDK and PD0325901 compared to that of single compound in a xenograft mouse model.
|
| | storage | Store at +4°C |
| | iMDK Preparation Products And Raw materials |
|